What is MIRM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 5.58B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MIRM?

P/E (TTM) is n/a and 52-week range is $63.23 to $130.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MIRM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MIRM?

The company profile lists revenue (TTM) near $595M, net income (TTM) near $-82.77B, EPS (TTM) near $-14.55 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Mirum Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Foster City, California, US, 61M shares outstanding, ISIN US6047491013 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Mirum Pharmaceuticals Inc

$MIRM

Health Care · Biotechnology

IR Run Scenarios

$86.01

+5.73%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Employees

369

Website

mirumpharma.com/

IPO

2019-07-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)